期刊文献+

三唑类抗真菌药物伏立康唑的合成 被引量:3

SYNTHESIS OF A TRIAZOLE ANTIFUNGAL DRUG VORICONAZOLE
下载PDF
导出
摘要 以氟代乙酸乙酯为原料,经缩合、溴代、加氢、拆分等反应合成了具有光学活性的抗真菌药物伏立康唑。中间体氟代丙酰基乙酸乙酯(FPEA)的合成条件是:n(氟乙酸乙酯):n(丙酰氯)=1.10:1,回流反应4 h,收率32%;6-乙基-5-氟嘧啶-4(3H)酮(EFPO)的合成条件是:n(FPEA):n(甲脒乙酸盐)=1:1.18,在0℃反应1 h,收率51.9%;6-乙基-4-氯-5-氟嘧啶(CEFP)的合成条件是:n(EFPO):n(POCl3)=1:2.2,回流反应3 h,收率82.8%;6-(1-溴乙基)-4-氯-5-氟嘧啶(CBFP)的合成:n(CEFP):n(NBS)=1:1.15,回流反应12 h,收率78%;(2R,3S/2S,3R)-3-(4-氯-5-氟嘧啶-6-基)-2-(2,4-二氟苯基)-1-(1H-1,2,4-三唑-1-基)丁-2-醇盐酸盐的合成条件:n(CBFP):n(氟康唑)=1.0:1.0,控制反应温度低于5℃,反应2 h,收率67.5%,将上述中间体盐用40%NaOH溶液调pH=11,经后处理得到伏立康唑白色结晶,收率74%。题述化合物经元素分析、1H NMR、FT-IR确证了结构,总收率1.3%。 A chiral voriconazole l- ( 2 R, 3S) -2- (2,4-difluorophenyl) - 3- (5-fluoro-4-pyrimidinyl) -1- ( 1 H-1,2,4-triazol-1-yl)-2-butan-2-ol] was synthesized from 1-fluoro ethyl acetate through steps involving condensation, bromination, hydrogenation, chiral resolution, etc. The conditions for the syntheses of the intermediates were investigated and the reaction conditions were optimized. The structure of the product was confirmed by elemental analysis, 1H NMR and FT-IR. The total yield of voriconazole was 1.3 %.
出处 《精细石油化工》 CAS CSCD 北大核心 2006年第4期33-36,共4页 Speciality Petrochemicals
基金 浙江省湖州市科技局项目(2005YG06)。
关键词 伏立康唑 合成 氟代乙酸乙酯 三唑类抗真菌药 voriconazole syntheses 1-fluoro ethyl acetate triazole antifungal drug
  • 相关文献

参考文献7

二级参考文献27

  • 1[11]Nesky MA, McDougal EC, Peacock Jr JE. Pseudallescheria boydii brain abscess successfully treated with voriconazole and surgical drainage:case report and literature review of central nervous system pseudallescheriasis[J]. Clin Infect Dis, 2000, 31:673.
  • 2[12]Schwartz S, Milatovic D, Thiel E. Successful treatment of cerebral aspergillosis with a novel triazole (voriconazole) in a patient with acute leukaemia[J]. British J Haematol, 1997, 97: 663.
  • 3[13]Poza G, Montoya J, Redondo C, et al. Meningitis caused by Pseudallescheria boydii treated with voriconzole[J]. Clin Infect Dis, 2000, 30: 981 - 982.
  • 4[14]Louis G, Vant H, Paul E, et al. Successful treatment with voriconazole of invasion aspergillosis in chronic granulomatous disease[J]. Am J Respir Crit Care Medicine, 1998, 157: 1694.
  • 5[15]Jabado N, Casanova J, Haddad E, et al. Invasive pulmonary infection due to Scedosporium apiospermum in two children chronic granulomatous disease [J]. Clin Infect Dis, 1998, 27:1437.
  • 6[1]Dickinson RP, Bell AS, Hitchcock CA, et al. Novel antifungal 2 aryl 1-(1H-1, 2, 4-triazol 1-yl)butan-2-ol derivatives with high activity against aspergillus fumigatus [J]. Bioorgan Med Chem Lett, 1996, 65: 2031.
  • 7[2]Richardson K, Bell A, Dickinson R, et al. UK - 109,496, a nov el, wide-spectrum triazole derivative for the treatment of fungal infections: synthesis and SAR (abstract F69) [A]. Presented at the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy[C]. San Francisco: 1995, 9: 17.
  • 8[3]Sanati H, Belanger P, Fratti R, et al. A new triazole , voriconazole (UK- 109,496), blocks sterol biosynthesis in Candida albicans and Cadida krusei [J]. Antimicrob Agents Chemother,1997, 41: 2492.
  • 9[4]Hoban DJ, Zhanel GG, Karlowsky JK. In vitro susceptibities of candida and Cryptococcus neoformans isolates from blood cultures of neutropenic patients[J]. Antimicrob Agents Chemother,1999, 43(6): 1463 - 1464.
  • 10[5]Abraham OC, Manavathu EK, Cutright JL, et al. In vitro susceptibilities of Aspergillus species to voriconazole, itraconazole,and amphotericin B[J]. Microbiol Infect Dis, 1999, 33 ( 1 ): 7-11.

共引文献42

同被引文献11

引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部